Clinical Efficacy of the Combined Use of Chemotherapy and Thymoxine- α1 at Differnet Doses on Cellular Immune Function in Patients with Lung Cancer

Objective To observe the effects of thymosin-α1 at different doses on cellular immune function of lung cancer patients receiving chemotherapy.Methods 105 patients with cancer were randomized into three groups: the treatment group 1 consisted of 35 lung cancer patients receiving chemotherapy plus thymoxineα1 1.6 mg/d by subcutaneous injection,the treatment group 2 consisted of 35 lung cancer patients receiving chemotherapy plus thymoxineα1 200 mg/d by intravenous infusion,while 35 lung cancer patients using chemotherapy alone were used as control group.Before and after chemotherapy,immune function of all patients were monitored by flowcytometry.Results Immune function of T cell subgroup and NK cell activity in control group significantly decreased after chemotherapy,while in the treatment group 1 and 2 significantly increased on the day 7 after chemotherapy(all P0.05).However,there were no differences between the treatment group1 and control group(P0.05) on immune function of T cell subgroup and NK cell activity on the day 14 after chemotherapy,while in the treatment group 2 significantly increased(all P 0.05).Conclusion The thymoxine-α1 at differnet dose in lung cancer patients can improve the immune function and the tolerance tochemotherapy in short time.